Pegylated Liposomal Mitomycin C Lipid-based Prodrug

Known as: PL-MLP 
A pegylated liposomal formulation comprised of a lipophilic prodrug of the antineoplastic antibiotic mitomycin C containing a cleavable disulfide… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2017
01220062017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The effect of a lipidated prodrug of mitomycin C (MLP) on the membrane of a pegylated liposome formulation (PL-MLP), also known… (More)
Is this relevant?
2016
2016
Mitomycin C (MMC) is a powerful anti-bacterial, anti-fungal and anti-tumor antibiotic, often active against multidrug resistant… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Mitomycin C (MMC) has potent cytotoxicity but cumulative toxicity limits widespread use. In animals, pegylated liposomal… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2015
2015
Pegylated liposomal (PL) mitomycin C lipid-based prodrug (MLP) has recently entered clinical testing. We studied here the… (More)
  • figure 1
  • table I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
BACKGROUND A mitomycin-C lipid-based prodrug (MLP) formulated in pegylated liposomes (PL-MLP) was previously reported to have… (More)
Is this relevant?
2006
2006
PURPOSE A lipid-based prodrug of mitomycin C [MMC; 2,3-(distearoyloxy)propane-1-dithio-4'-benzyloxycarbonyl-MMC] was designed for… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?